Glytec has received its fourth clearance from the US Food and Drug Administration (FDA) for its diabetes therapy management software, Glucommander.
The new clearance covers a series of new capabilities added to Glucommander, which is the core software of the firm’s eGlycemic Management System (eGMS).
eGMS is designed to support insulin management across all settings for both inpatients and outpatients, allowing standardisation of care and effective interventions.
Glucommander’s enhancements include a titration module for inpatients that are given enteral nutrition, an insulin-to-carb ratio titration option to complement the current fixed meal bolus option for outpatients and several user interface improvements.
An upgrade intended for optimised inpatient transition from intravenous to subcutaneous therapy and another for better flexibility in messaging a dose adjustment to outpatients have also been added to the software.
Glytec president and CEO Bob Leonard said: “We have fundamentally built a technology category from the ground up, and this latest FDA clearance demonstrates our steadfast commitment to continuous innovation.
“Glytec’s platform provides substantive value to healthcare organisations and their patients, markedly improving safety while producing annualised savings as high as $20,000 per licensed bed in the acute care setting and $2,470 per patient from a chronic care perspective.”
Glucommander features complex algorithms to aid the delivery of intravenous and subcutaneous insulin for adult and paediatric patients.
The platform can support all types of insulin such as long-acting basal preparations, NPH (intermediate-acting), rapid-acting analogues, and regular insulin.
It provides personalised dosing recommendations to individual patients and can perform titration for outpatients that are prescribed with a basal insulin regimen or a basal bolus insulin regimen.
Image: Glytec’s comprehensive, cloud-hosted eGlycemic Management System. Photo: courtesy of Glytec.